Pitolisant for the treatment of narcolepsy with or without cataplexy.
Copyright policy )Pitolisant for the treatment of narcolepsy with or without cataplexy.
Since March 2016, a new treatment option for adult patients with narcolepsy – with or without cataplexy – has been granted marketing authorization in Europe. Pitolisant (Wakix®) is an inverse agonst at the histamine-3 (H3) receptor. In clinical studies, tests for measurement of wakefulness and attention, pitolisant showed significantly better results in comparison with placebo and similar results in comparison with modafinil. Pitolisant is well tolerated. Postmarketing analyses have to collect data about the long-term safety of pitolisant when used in a real-life setting.
Adult, Male, Dose-Response Relationship, Drug, Contraindications, Administration, Oral, Piperidines, Humans, Attention, Female, Arousal, Histamine H3 Antagonists, Narcolepsy, Randomized Controlled Trials as Topic
Adult, Male, Dose-Response Relationship, Drug, Contraindications, Administration, Oral, Piperidines, Humans, Attention, Female, Arousal, Histamine H3 Antagonists, Narcolepsy, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!